Medical Complications of Psychiatric Treatment

Critical Care Clinics

Volumn 24, Issue 4, 2008, Pages 635-656

  Smith, Felicia A ^a,b,c   Wittmann, Curtis W ^a,c   Stern, Theodore A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Transplant Psychiatry Service   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CITALOPRAM; DANTROLENE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; ISOCARBOXAZID; LEVODOPA; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PETHIDINE; PHENELZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; UNINDEXED DRUG;

AGRANULOCYTOSIS; BLEEDING; BLOOD DYSCRASIA; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DELIRIUM; DEMENTIA; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIAPHORESIS; DIARRHEA; DRUG INTOXICATION; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPERTHERMIA; HYPONATREMIA; HYPOTHERMIA; LIVER DYSFUNCTION; LUNG EMBOLISM; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; MUSCLE RIGIDITY; MYOCARDITIS; NAUSEA; NEPHROTOXICITY; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT CARE; PRIAPISM; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RASH; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SWEATING; TARDIVE DYSKINESIA; TERATOGENESIS; THERMOREGULATION; THYROID DISEASE; URINARY DYSFUNCTION; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DRUG INTERACTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSYCHOTROPIC DRUGS;

EID: 53449098848     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2008.05.004     Document Type: Review

References (76)

1. Nisijima K., Shioda K., and Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res 162 (2007) 81-104
2. Ananth J., Parameswaran S., and Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 10 18 (2004) 2219-2229
3. Caroff S.N., and Mann S.C. Neuroleptic malignant syndrome and malignant hyperthermia. Anaesth Intensive Care 21 4 (1993) 477-478
4. Fricchione G.L., Huffman J.C., Stern T.A., et al. Catatonia, neuroleptic malignant syndrome, and serotonin syndrome. In: Stern T.A., Fricchione G.L., and Cassem N.H. (Eds). Massachusetts General Hospital handbook of general hospital psychiatry. 5th edition (2004), Mosby, Philadelphia 513-530
5. Robinson M.J., and Owen J.A. Psychopharmacology. In: Levenson J.L. (Ed). The American Psychiatric Publishing textbook of psychosomatic medicine (2005), American Psychiatric Publishing, Arlington (VA) 871-922
6. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 11 (2005) 1112-1120
7. Gillman P.K. The serotonin syndrome and its treatment. J Psychopharmacol 13 1 (1999) 100-109
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. text revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
9. Rudolph J.L., Salow M.J., Angelini M.C., et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168 5 (2008) 508-513
10. Marcangelo M.J., and Ovsiew F. Psychiatric aspects of epilepsy. Psychiatr Clin North Am 30 4 (2007) 781-802
11. Johnston J.A., Lineberry C.G., Ascher J.A., et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 52 11 (1991) 450-456
12. Alper K., Schwartz K.A., Kolts R.L., et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62 4 (2007) 345-354
13. Pisani F., Oteri G., Costa C., et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 25 2 (2002) 91-110
14. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 3 (2006) 191-210
15. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 15 (2005) 1934-1943
16. Gill S.S., Rochon P.A., Herrmann N., et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330 7489 (2005) 445
17. Herrmann N., Mamdani M., and Lanctot K.L. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161 6 (2004) 1113-1115
18. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 22 (2005) 2335-2341
19. Haddad P.M., and Dursun S.M. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 23 Suppl 1 (2008) 15-26
20. Noskin O., Jafarimojarrad E., Libman R.B., et al. Diffuse cerebral vasoconstriction (Call-Fleming syndrome) and stroke associated with antidepressants. Neurology 67 1 (2006) 159-160
21. Singhal A.B., Caviness V.S., Begleiter A.F., et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 58 1 (2002) 130-133
22. Singh H., Levinson D.F., Simpson G.M., et al. Acute dystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 10 6 (1990) 389-396
23. Tandon R. Safety and tolerability: how do newer generation atypical antipsychotics compare?. Psychiatr Q 73 4 (2002) 297-311
24. Lieberman J.A., Saltz B.L., Johns C.A., et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158 (1991) 503-510
25. Martin-Latry K., Goumy M., Latry P., et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur Psychiatry 22 6 (2007) 335-338
26. Alpert J.E., Fava M., and Rosenbaum J.F. Psychopharmacologic issues in the medical setting. In: Stern T.A., Fricchione G.L., and Cassem N.H. (Eds). Massachusetts General Hospital handbook of general hospital psychiatry. 5th edition (2004), Mosby, Philadelphia 513-530
27. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23 Suppl 1 (2008) 3-14
28. Haas S.J., Hill R., Krum H., et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30 1 (2007) 47-57
29. Killian J.G., Kerr K., Lawrence C., et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 354 9193 (1999) 1841-1845
30. Prod Info Fazaclo orally disintegrating tablets, 2007.
31. Prod Info Risperidal oral solution, 2007; Prod Info Risperidal Consta long-acting IM injection, 2007.
32. Davydov L., and Botts S.R. Clozapine-induced hypersalivation. Ann Pharmacother 34 5 (2000) 662-665
33. Koller E.A., Cross J.T., Doraiswamy P.M., et al. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 23 9 (2003) 1123-1130
34. Bryant III A.E., and Dreifuss F.E. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 46 2 (1996) 465-469
35. Wadzinski J., Franks R., Roane D., et al. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 20 5 (2007) 499-502
36. Prod Info Serzone, 2001.
37. Derby L.E., Gutthann S.P., Jick H., et al. Liver disorders in patients receiving chlorpromazine or isoniazid. Pharmacotherapy 13 4 (1993) 353-358
38. Schmidt S., Welcker M., Greil W., et al. Carbamazepine-induced systemic lupus erythematosus. Br J Psychiatry 161 (1992) 560-561
39. Zucker S., Zarrabi H.M., Schubach W.H., et al. Chlorpromazine-induced immunopathy: progressive increase in serum IgM. Medicine (Baltimore) 69 2 (1990) 92-100
40. Quismorio F.P., Bjarnason D.F., Kiely W.F., et al. Antinuclear antibodies in chronic psychotic patients treated with chlorpromazine. Am J Psychiatry 132 11 (1975) 1204-1206
41. Marraffa J.M., and Guharoy R. Lymphadenopathy secondary to lamotrigine (Lamictal). Vet Hum Toxicol 44 5 (2002) 276-277
42. Prod Info Cymbalta delayed-release oral capsules, 2007.
43. Boton R., Gaviria M., and Batlle D.C. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10 5 (1987) 329-345
44. Chugh S., and Yager H. End-stage renal disease after treatment with lithium. J Clin Psychopharmacol 17 6 (1997) 495-497
45. Presne C., Fakhouri F., Noel L.H., et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 64 2 (2003) 585-592
46. Dong X., Leppik I.E., White J., et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 65 12 (2005) 1976-1978
47. Jacob S., and Spinler S.A. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 40 9 (2006) 1618-1622
48. Goff D.C., Sullivan L.M., McEvoy J.P., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80 1 (2005) 45-53
49. Henderson D.C. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep 2 2 (2002) 135-140
50. Henderson D.C., Cagliero E., Gray C., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157 6 (2000) 975-981
51. Henderson D.C. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 16 2 (2002) 77-89
52. Henderson D.C., Cagliero E., Copeland P.M., et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 68 4 (2007) 533-541
53. Bocchetta A., and Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2 (2006) 23
54. Becker M., Axelrod D.J., Oyesanmi O., et al. Hematologic problems in psychosomatic medicine. Psychiatr Clin North Am 30 4 (2007) 739-759
55. Guzelcan Y., and Scholte W.F. [Clozapine-induced agranulocytosis: genetic risk factors and an immunologic explanatory model]. Tijdschr Psychiatr 48 4 (2006) 295-302 [in Dutch]
56. Sedky K., Shaughnessy R., Hughes T., et al. Clozapine-induced agranulocytosis after 11 years of treatment. Am J Psychiatry 162 4 (2005) 814
57. Serebruany V.L. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med 119 2 (2006) 113-116
58. de Abajo F.J., Montero D., Rodriguez L.A., et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 98 3 (2006) 304-310
59. Meijer W.E., Heerdink E.R., Nolen W.A., et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 164 21 (2004) 2367-2370
60. Skop B.P., and Brown T.M. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 37 1 (1996) 12-16
61. Borras L., Eytan A., de Timary P., et al. Pulmonary thromboembolism associated with olanzapine and risperidone. J Emerg Med 35 2 (2008) 159-161
62. Lacut K., Le Gal G., Couturaud F., et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 21 6 (2007) 643-650
63. del Conde I., and Goldhaber S.Z. Pulmonary embolism associated with olanzapine. Thromb Haemost 96 5 (2006) 690-691
64. Yang T.Y., Chung K.J., Huang T.L., et al. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med 27 1 (2004) 27-29
65. Parkin L., Skegg D.C., Herbison G.P., et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 12 8 (2003) 647-652
66. Pan R., John V., and Hagg S. Clozapine and pulmonary embolism. Acta Psychiatr Scand 108 1 (2003) 76-77 [discussion: 77]
67. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 24 (1995) 1600-1607
68. Arif H., Buchsbaum R., Weintraub D., et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68 20 (2007) 1701-1709
69. Yonkers K.A., Wisner K.L., Stowe Z., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161 4 (2004) 608-620
70. Newport D.J., Viguera A.C., Beach A.J., et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 162 11 (2005) 2162-2170
71. Jones K.L., Lacro R.V., Johnson K.A., et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 320 25 (1989) 1661-1666
72. Morrell M.J. Pregnancy and antiepileptic drugs. Curr Neurol Neurosci Rep 1 4 (2001) 359-360
73. Newport D.J., Calamaras M.R., DeVane C.L., et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164 8 (2007) 1214-1220
74. McKenna K., Koren G., Tetelbaum M., et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66 4 (2005) 444-449 quiz 546
75. Sood S., James W., and Bailon M.J. Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 23 1 (2008) 9-17
76. Jayaram G., and Rao P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics 46 4 (2005) 367-369